TrialDiabetes, obesity & metabolism2022

Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC).

Bin Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.